Advagen Inc.
This article was originally published in Start Up
Executive Summary
A re-start of DirectGene Inc., Advagen Inc. will marry its gene therapy for prostate cancer to newly in-licensed IP covering small peptide ligands with an affinity for the PSMA receptor. The company believes its new platform will greatly enhance adenovirus targeting and facilitate systemic delivery of gene therapies for a variety of cancers.